| | |
Univariate
|
Multivariate
|
|---|
| | |
Hazard ratio
|
(95 % CI)
|
P-value
|
Hazard ratio
|
(95 % CI)
|
P-value
|
|---|
|
Progression-free survival
|
|
EILD
|
Yes
|
3.35
| |
0.0029
|
3.42
| |
0.0079
|
| |
No
| |
1.51–7.44
| | |
1.38–8.47
| |
|
Age
| ≦56≦56 |
0.64
| |
0.11
|
0.67
| |
0.20
|
| |
>56
| |
0.38–1.10
| | |
0.36–1.24
| |
|
PS
|
0
|
0.84
| |
0.58
|
0.68
| |
0.24
|
| |
1,2
| |
0.46–1.55
| | |
0.36–1.30
| |
|
Comorbid disease
|
Yes
|
1.59
| |
0.15
|
1.47
| |
0.32
|
| |
No
| |
0.85–2.99
| | |
0.69–3.15
| |
|
DFI
| ≦2.8≦2.8 |
1.81
| |
0.035
|
1.79
| |
0.08
|
| |
>2.8
| |
1.04–3.15
| | |
0.93–3.45
| |
|
BMI
|
>25
|
1.84
| |
0.073
|
0.86
| |
0.71
|
| | ≦25≦25 | |
0.95–3.57
| | |
0.38–1.93
| |
|
HR (ER/PgR) status
|
Positive
|
1.23
| |
0.46
|
1.12
| |
0.73
|
| |
Negative
| |
0.71–2.13
| | |
0.58–2.15
| |
|
HER2 status
|
Negative
|
1.69
| |
0.14
|
2.14
| |
0.054
|
| |
Positive
| |
0.84–3.39
| | |
0.99–4.66
| |
|
Overall survival
|
|
EILD
|
Yes
|
3.93
| |
0.063
|
3.42
| |
0.13
|
| |
No
| |
0.93–16.6
| | |
0.71–16.44
| |
|
Age
| ≦56≦56 |
0.81
| |
0.59
|
0.89
| |
0.78
|
| |
>56
| |
0.38–1.73
| | |
0.38–2.09
| |
|
PS
|
0
|
1.73
| |
0.20
|
1.51
| |
0.36
|
| |
1,2
| |
0.75–4.02
| | |
0.63–3.63
| |
|
Comorbid disease
|
Yes
|
1.14
| |
0.76
|
1.17
| |
0.76
|
| |
No
| |
0.48–2.71
| | |
0.44–3.09
| |
|
DFI
| ≦2.8≦2.8 |
2.52
| |
0.037
|
1.95
| |
0.19
|
| |
>2.8
| |
1.06–5.98
| | |
0.73–5.25
| |
|
BMI
|
>25
|
1.47
| |
0.42
|
0.87
| |
0.79
|
| | ≦25≦25 | |
0.59–3.62
| | |
0.32–2.40
| |
|
HR (ER/PgR) status
|
Positive
|
1.54
| |
0.28
|
0.97
| |
0.95
|
| |
Negative
| |
0.71–3.34
| | |
0.42–2.28
| |
|
HER2 status
|
Negative
|
2.49
| |
0.057
|
2.20
| |
0.13
|
| |
Positive
| |
0.97–6.39
| | |
0.79–3.09
| |
- Abbreviation: 95 % CI 95 % confidence interval, EILD eribulin-induced liver dysfunction, PS performance status, DFI disease free interval, BMI body mass index, HR hormone receptor, ER estrogen receptor, PgR progesterone receptor, HER2 human epidermal growth factor receptor 2
